Last $2.27 USD
Change Today +0.04 / 1.79%
Volume 4.4K
IMI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

intermolecular inc (IMI) Snapshot

Open
$2.27
Previous Close
$2.23
Day High
$2.28
Day Low
$2.25
52 Week High
11/25/13 - $5.80
52 Week Low
10/27/14 - $1.93
Market Cap
108.0M
Average Volume 10 Days
53.2K
EPS TTM
$-0.41
Shares Outstanding
47.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERMOLECULAR INC (IMI)

intermolecular inc (IMI) Related Bloomberg News

View More Bloomberg News

intermolecular inc (IMI) Related Businessweek News

No Related Businessweek News Found

intermolecular inc (IMI) Details

Intermolecular, Inc. develops and applies high productivity combinatorial (HPC) research and development technologies for the semiconductor and clean energy industries. Its HPC platform includes wet processing tools that apply HPC methods to fluids-based applications, such as cleans, deposition and wet etch, self-assembly, and surface treatment processes; and dry processing tools, which apply HPC methods to vapor-based applications for primary, secondary, and tertiary screening. The company’s HPC platform also comprise automated characterization systems to characterize the substrates processed by Tempus HPC processing tools and generates experimental data while matching processing throughput; and informatics software comprising workflow management software, analysis and reporting software, security and collaboration management software, and integration services. It serves semiconductor device, semiconductor materials and equipment, and clean-energy companies in the United States, Japan, Europe, the Middle East, and the APAC. The company was formerly known as The BEP Group, Inc. and changed its name to Intermolecular, Inc. in November 2004. Intermolecular, Inc. was founded in 2004 and is headquartered in San Jose, California.

253 Employees
Last Reported Date: 03/10/14
Founded in 2004

intermolecular inc (IMI) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $73.7K
Senior Vice President of Customer CDPs
Total Annual Compensation: $300.4K
Vice-President of Finance and Corporate Contr...
Total Annual Compensation: $239.6K
Senior Vice President of Emerging Technology
Total Annual Compensation: $214.9K
Chief Technology Officer
Total Annual Compensation: $280.0K
Compensation as of Fiscal Year 2013.

intermolecular inc (IMI) Key Developments

Intermolecular, Inc. Amends Two Collaborative Development Program Agreements with Guardian Industries Corp

On October 30, 2014, Intermolecular, Inc. amended two collaborative development program (CDP) agreements that the company had previously entered into with Guardian Industries Corp. The company entered into first CDP agreement with Guardian in February 2010 to collaborate on research and development tasks relating to liquid coatings for flat glass. Intermolecular, Inc. entered into second CDP agreement with Guardian in July 2010 to collaborate on research and development tasks relating to sputtered coatings for flat glass. Prior to this amendment, the agreements were amended effective January 1, 2012 (first amendment). This most recent amendment is effective as of February 1, 2015, includes a reduction in the company resources dedicated to the CDP Agreements and a corresponding reduction in the monthly program fees paid by Guardian. Additionally, the Fourth Amendment includes a new licensing and royalty structure that will be applied to all past and future work done under the CDP Agreements, subject to certain maximum levels.

Intermolecular, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Fourth Quarter of 2014

Intermolecular, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. The company's revenue for the third quarter of 2014 was $10.9 million, a decline of 39% from $17.7 million in the year-ago period, but up from the prior quarter's revenue of $9.9 million. Collaborative development program (CDP) revenue was $7.7 million for the quarter, compared to $11.2 million in the prior year period. Licensing and royalty revenue was $3.2 million, compared to $3.8 million for the same period a year ago. For the third quarter of 2014, the company reported a net loss of $5.0 million, or $0.11 per share, compared to a net loss of $2.2 million, or $0.05 per share, for the third quarter of 2013 and a net loss of $6.9 million, or $0.15 per share, in the second quarter of 2014. On a non-GAAP basis, the company reported a net loss of $3.2 million, or $0.07 per share, compared to a net loss of $0.8 million, or $0.02 per share, in the third quarter of 2013, and a net loss of $5.3 million, or $0.11 per share, in the second quarter of 2014. Operating loss was $4,790,000 against $1,975,000 a year ago. Loss before provision for income taxes was $4,962,000 against $2,145,000 a year ago. Non-GAAP operating loss was $3,054,000 against $651,000 a year ago. For the nine months period, the company reported total revenue of $36,694,000 against $51,789,000 a year ago. Operating loss was $15,121,000 against $3,786,000 a year ago. Loss before provision for income taxes was $15,666,000 against $4,369,000 a year ago. Net loss was $15,673,000 or $0.34 per diluted share against $4,401,000 or $0.10 per diluted share a year ago. Cash flows used in operations for the third quarter of 2014 were $2.3 million. The company invested $0.6 million in capital expenditures in the third quarter, and ended the quarter with cash and investments of $66.1 million. Purchase of property and equipment was $2,568,000 against $9,054,000 a year ago. Non-GAAP operating loss was $9,231,000 against income of $302,000 a year ago. Non-GAAP net loss was $9,783,000 or $0.21 per diluted share against $313,000 or $0.01 per diluted share a year ago. The company provided earnings guidance for the fourth quarter of 2014. The company projects revenue in the range of $10 to $11 million. This revenue projection includes approximately $9.6 million from reported backlog as of September 30, 2014. Non-GAAP net loss, excluding stock-based compensation expense, is projected between a non-GAAP net loss of $4.5 million and $5.5 million, or between $0.10 per share to $0.12 per share, on approximately 47 million basic shares outstanding.

Intermolecular, Inc. to Report Q3, 2014 Results on Oct 31, 2014

Intermolecular, Inc. announced that they will report Q3, 2014 results at 8:30 AM, US Eastern Standard Time on Oct 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMI:US $2.27 USD +0.04

IMI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMI.
View Industry Companies
 

Industry Analysis

IMI

Industry Average

Valuation IMI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERMOLECULAR INC, please visit www.intermolecular.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.